Clinical Trials Logo

Uveitis clinical trials

View clinical trials related to Uveitis.

Filter by:

NCT ID: NCT04150770 Active, not recruiting - Uveitis Clinical Trials

A Clinical Trial of Infliximab for Childhood Uveitis

Start date: January 2017
Phase: Phase 4
Study type: Interventional

This project is designed to test the hypothesis that infliximab is clinically useful for patients with refractory childhood uveitis.

NCT ID: NCT04148365 Completed - Uveitis Clinical Trials

Medication Compliance in the Paediatric Uveitis Population Reported by the Patients and Parents

Start date: February 14, 2020
Phase:
Study type: Observational

Little is known about eye drop regime adherence in the paediatric population. In particular, no previous research has investigated this in the paediatric uveitis population, a group who can require doses up to six times daily, and at frequencies that change month to month. The aim of the study is to quantify the range of adherence to eye drop medication, and to investigate some of the reasons for non-compliance in a child specific study. By learning more about compliance, this will help create treatments that are better suited to children. The study will recruit 50 children receiving eye drop treatment. After an interval of 1 week or more the children and their parents will be asked to complete a questionnaire about the frequency of the drops prescribed, and the frequency that they have used over the last interval. It will also ask questions about difficulties encountered administering the drops. Changes in eye drop bottle weight will be measured during the interval and the result compared. The information gathered from the questionnaires will be used to compare reports of adherence between the parent and child, the child's age and the bottle weight. The reasons reported for difficulties with adherence will also be reported. This is a preliminary investigatory study to identify whether an issue with medication non-adherence exists. The findings will be used to tailor further research into this area.

NCT ID: NCT04126850 Not yet recruiting - Behçet Disease Clinical Trials

Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease

Start date: November 1, 2019
Phase:
Study type: Observational

This study aimed to discover the composition on the microbiome in several sites of the human body; and to find out the difference in microbiome composition on ocular fluid, blood, and feces before and after therapy in uveitis patient with history of autoimmune disease (Behcet and Vogt-Koyanagi-Harada) and idiopathic uveitis

NCT ID: NCT04117698 Not yet recruiting - Uveitis, Anterior Clinical Trials

Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)

URBA
Start date: November 1, 2019
Phase: Phase 3
Study type: Interventional

Uveitis accounts for 15% of the causes of legal blindness. The etiological diagnosis of uveitis is difficult because of the poor bacteriological performance of aqueous or vitreous fluid analysis. At the end of a medical and paramedical check-up, oriented by the typology of uveitis, a clinical situation is frequently encountered: idiopathic uveitis with a Quantiferon test (QFN) positive orienting to an old or recent contact with tuberculosis. Ocular tuberculosis is often characterized by a partial and transient response to corticosteroid therapy (local or general), due to predominant hypersensitivity phenomena and low inoculum. Therefore, antitubercular treatment is recommended for idiopathic posterior uveitis with positive QFN. This treatment of 6-9 months has shown, in combination with systemic corticosteroids, its effectiveness on ocular inflammation and significant decrease in recurrence frequency. For previous uveitis with QFN positive, there is no study or recommendation in the low endemic countries on the indication of anti-tuberculosis drugs and practices are variable. Tuberculous anterior uveitis is distinguished by high rate of relapses and chronic uveitis upon discontinuation of topic corticosteroid therapy that exposes to broad posterior synechiae leading to an ocular functional impairment. Optimizing the management of recurrent anterior uveitis is therefore crucial. The aim of this prospective, randomized, controlled, open, two parallel arm trial is to compared antitubercular treatment "add-on "of local corticosteroid therapy to Local Corticosteroid Therapy Only in patients with recurrent or chronic anterior uveitis. Primary outcome is the treatment succes defined as uveitis recovery at 3 months and the absence of recurrence at 18 months of follow-up.

NCT ID: NCT04105452 Not yet recruiting - Clinical trials for Non-infectious Uveitis

Study to Evaluate PL8177 in Subjects With Non Infectious Uveitis (NIU)

Start date: December 31, 2019
Phase: Phase 2
Study type: Interventional

The study is a Phase 2, open-label, randomized, 4-arm, parallel group study in subjects with active non-infectious uveitis. Subjects will be randomized to receive either 0.1 mg or 1.0 mg of PL8177 SC injection as 2 single doses 48 hours apart (Group A) or as a single dose for 4 weeks (4 doses) (Group B). A total of 40 subjects are planned to be enrolled with 20 participating in each Group.

NCT ID: NCT04101604 Recruiting - Clinical trials for Diabetic Retinopathy

Biomarkers of Common Eye Diseases

Start date: September 26, 2019
Phase:
Study type: Observational

To identify biomarkers of common eye diseases based on single-cell sequencing technologies using PBMC samples. These diseases include uveitis, diabetic retinopathy, age-related macular degeneration and polypoid choroidal vasculopathy. Our study may provide new insight into the underlying mechanisms, and reveal novel predictors and intervention targets for the diagnosis, prognosis and treatment of these diseases.

NCT ID: NCT04088409 Active, not recruiting - Uveitis Clinical Trials

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Start date: October 16, 2019
Phase: Phase 3
Study type: Interventional

The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.

NCT ID: NCT04088019 Recruiting - Clinical trials for Anti-Tuberculous Drug Reaction

Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive

Start date: October 30, 2019
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to determine the proportion of clinical improvement, the score changing of type 1 interferon selected gene expression, and analysis of transcriptomics profiling in patients with idiopathic uveitis positive IGRA before and after receiving Anti-Tuberculosis Therapy (ATT). Hopefully, by conducting this research, we are able to provide valid data that demonstrate the advantages/disadvantages usage of Anti-Tuberculosis Therapy in patients with idiopathic uveitis IGRA positive that correlate with type I IFN. This research is a part of our efforts in discovering bio-marker candidates of idiopathic uveitis IGRA positive clinical patients who will benefit from the ATT administration.

NCT ID: NCT04018599 Completed - Clinical trials for Rheumatoid Arthritis

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Start date: July 15, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection of 40 mg.

NCT ID: NCT03971279 Completed - Posterior Uveitis Clinical Trials

Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis

Start date: January 1, 2017
Phase:
Study type: Observational

VKH disease is a vision threatening condition.The investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent VKH posterior uveitis.